RU2764702C2 - Нейроактивные соединения и способы их применения - Google Patents

Нейроактивные соединения и способы их применения Download PDF

Info

Publication number
RU2764702C2
RU2764702C2 RU2017115849A RU2017115849A RU2764702C2 RU 2764702 C2 RU2764702 C2 RU 2764702C2 RU 2017115849 A RU2017115849 A RU 2017115849A RU 2017115849 A RU2017115849 A RU 2017115849A RU 2764702 C2 RU2764702 C2 RU 2764702C2
Authority
RU
Russia
Prior art keywords
substituted
unsubstituted
alkyl
group
hydrogen
Prior art date
Application number
RU2017115849A
Other languages
English (en)
Russian (ru)
Other versions
RU2017115849A (ru
RU2017115849A3 (enExample
Inventor
Майкл К. КВИРК
Джеймс Дж. ДОЭРТИ
БОТЕЛЬЯ Габриэль МАРТИНЕС
Original Assignee
Сейдж Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейдж Терапьютикс, Инк. filed Critical Сейдж Терапьютикс, Инк.
Publication of RU2017115849A publication Critical patent/RU2017115849A/ru
Publication of RU2017115849A3 publication Critical patent/RU2017115849A3/ru
Application granted granted Critical
Publication of RU2764702C2 publication Critical patent/RU2764702C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2017115849A 2014-10-07 2015-10-07 Нейроактивные соединения и способы их применения RU2764702C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
US62/060,932 2014-10-07
PCT/US2015/054551 WO2016057713A1 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof

Publications (3)

Publication Number Publication Date
RU2017115849A RU2017115849A (ru) 2018-11-13
RU2017115849A3 RU2017115849A3 (enExample) 2019-05-15
RU2764702C2 true RU2764702C2 (ru) 2022-01-19

Family

ID=55653736

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017115849A RU2764702C2 (ru) 2014-10-07 2015-10-07 Нейроактивные соединения и способы их применения

Country Status (17)

Country Link
US (2) US20170304321A1 (enExample)
EP (1) EP3204011A4 (enExample)
JP (3) JP2017530982A (enExample)
KR (1) KR20170065637A (enExample)
CN (2) CN107405352A (enExample)
AU (2) AU2015330906A1 (enExample)
BR (1) BR112017007053A2 (enExample)
CA (1) CA2963938C (enExample)
IL (2) IL292465B2 (enExample)
MX (2) MX388694B (enExample)
MY (1) MY202135A (enExample)
PE (1) PE20170907A1 (enExample)
PH (1) PH12017500639A1 (enExample)
RU (1) RU2764702C2 (enExample)
SG (2) SG10202011773UA (enExample)
WO (1) WO2016057713A1 (enExample)
ZA (1) ZA201702545B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
WO2017007832A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
IL298681A (en) * 2016-08-02 2023-01-01 Univ Virginia Commonwealth Preparations
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) * 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2026102175A1 (en) * 2024-11-06 2026-05-15 Sage Therapeutics, LLC Nmda receptor-modulatory compounds and methods of use thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059961A2 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
US20110160223A1 (en) * 2008-05-09 2011-06-30 Dingledine Raymond J NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders
AR084401A1 (es) * 2010-08-09 2013-05-15 Hoffmann La Roche COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
US20140045943A1 (en) * 2008-12-03 2014-02-13 Naurex, Inc. Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof
US8673843B2 (en) * 2010-02-11 2014-03-18 Northwestern University NMDA receptors modulators and uses thereof
WO2014120786A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
HUE062616T2 (hu) * 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
JP6628745B2 (ja) * 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
EP3166613A4 (en) * 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
WO2017007832A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2009059961A3 (en) * 2007-11-06 2010-01-21 N.V. Organon A method of hormone suppression in humans
WO2009059961A2 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
US20110160223A1 (en) * 2008-05-09 2011-06-30 Dingledine Raymond J NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders
US20140045943A1 (en) * 2008-12-03 2014-02-13 Naurex, Inc. Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2010088414A3 (en) * 2009-01-28 2011-03-31 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A3 (en) * 2009-09-01 2011-07-21 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
US8673843B2 (en) * 2010-02-11 2014-03-18 Northwestern University NMDA receptors modulators and uses thereof
AR084401A1 (es) * 2010-08-09 2013-05-15 Hoffmann La Roche COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
WO2014120786A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
БЕЛИКОВ В.Г. Фармацевтическая химия. В 2 ч. Ч.1. Общая фармацевтическая химия: Учеб. для фармац. ин-тов фак. мед. ин-тов. - М.: Высш. шк., 1993. - 432 с. *

Also Published As

Publication number Publication date
CA2963938C (en) 2023-10-24
MY202135A (en) 2024-04-05
MX388694B (es) 2025-03-20
AU2021200721A1 (en) 2021-03-04
CN112121171A (zh) 2020-12-25
SG10202011773UA (en) 2021-01-28
ZA201702545B (en) 2019-06-26
US20170304321A1 (en) 2017-10-26
BR112017007053A2 (pt) 2018-06-19
MX2021011939A (es) 2021-11-03
RU2017115849A (ru) 2018-11-13
US20230218638A1 (en) 2023-07-13
EP3204011A1 (en) 2017-08-16
IL251505A0 (en) 2017-05-29
AU2015330906A1 (en) 2017-04-27
JP2017530982A (ja) 2017-10-19
RU2017115849A3 (enExample) 2019-05-15
IL292465B1 (en) 2025-02-01
SG11201702799UA (en) 2017-05-30
PH12017500639A1 (en) 2017-09-25
CA2963938A1 (en) 2016-04-14
IL251505B (en) 2022-05-01
KR20170065637A (ko) 2017-06-13
EP3204011A4 (en) 2018-06-20
NZ730862A (en) 2024-01-26
CN107405352A (zh) 2017-11-28
JP2022033285A (ja) 2022-02-28
IL292465B2 (en) 2025-06-01
WO2016057713A1 (en) 2016-04-14
AU2021200721B2 (en) 2023-06-01
IL292465A (en) 2022-06-01
JP2020196759A (ja) 2020-12-10
PE20170907A1 (es) 2017-07-12
MX2017004684A (es) 2017-06-30

Similar Documents

Publication Publication Date Title
AU2021200721B2 (en) Neuroactive compounds and methods of use thereof
JP7602513B2 (ja) オキシステロールおよびそれらの使用の方法
JP7602512B2 (ja) オキシステロールおよびそれらの使用の方法
RU2754130C2 (ru) Оксистеролы и способы их применения
AU2016289965A1 (en) Oxysterols and methods of use thereof
RU2850468C2 (ru) Оксистеролы и способы их применения
HK40051330B (en) Oxysterols and methods of use thereof
HK40051330A (en) Oxysterols and methods of use thereof
HK40053565B (en) Oxysterols and methods of use thereof
HK1247563B (en) Oxysterols and methods of use thereof